Biogen (BIIB) PT Lowered to $265 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $249.65 +2.29%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Canaccord Genuity analyst Sumant Kulkarni lowered the price target on Biogen (NASDAQ: BIIB) to $265.00 (from $298.00) while maintaining a Buy rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $275 at Freedom Broker
- Argus Upgrades Biogen (BIIB) to Buy
- Churchill Downs (CHDN) PT Lowered to $131 at Stifel, Stays on Stifel Select List
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
